Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome

Simple item page
dc.contributor.authorVasquez, Dario H.
dc.contributor.authorAltamirano, Juan C.
dc.contributor.authorCasaus, Angel
dc.contributor.authorDel Valle, Rodrigo A.
dc.contributor.authorGonzalez, Roberto
dc.contributor.authorGonzalez-De la Rosa, Alejandro
dc.contributor.authorNavarro-Partida, Jose
dc.contributor.authorVasquez, Martin A.
dc.contributor.authorSantos, Arturo
dc.date.accessioned2025-01-23T21:22:58Z
dc.date.available2025-01-23T21:22:58Z
dc.date.issued2018
dc.description.abstractPurpose: To report surgical outcomes in a series of cases with symptomatic vitreomacular traction thatmet MIVI-TRUST (Microplasmin for intravitreous injection-traction release without surgical treatment) criteria for ocriplasmin use who underwent primary 25-gauge vitrectomy.
dc.description.abstractMaterials and Methods: A single-center retrospective chart review study was performed in patients who underwent primary 25-gauge vitrectomy for symptomatic vitreomacular traction (VTM) from January 2013 through January 2016. Pre- and postoperative visual acuity (measured by the early treatment diabetic retinopathy acuity test), and posterior hyaloid focal attachment to the macula (demonstrated by high-definition optical coherence tomography) were analyzed. In addition, intra-and postoperative complications were obtained from medical records.
dc.description.abstractResults: Fifteen consecutive cases of symptomatic VMT traction that underwent primary 25-gauge vitrectomy were included. All met the MIVI-TRUST criteria for ocriplasmin use. In all cases, VMT resolution, macular hole closure, and improvement in best corrected visual acuity (BCVA) were observed. Mean visual acuity improved from 56.53 +/- 16.04 letters at baseline to 73.13 +/- 7.46 letters at 24 weeks of follow-up. The mean BCVA improvement from baseline was 16.60 letters (range 6-44), which was statistically significant (P < 0.0001). Ten of fifteen patients (66.6%) showed significant improvement of their BCVA to 20/40 or better (70 or more in ETDRS visual acuity test). No significant intra-or postoperative complications were documented.
dc.description.abstractConclusions: Primary 25-gauge pars plana vitrectomy in eyes with symptomatic vitreomacular traction is able to efficiently resolve VMT and macular holes, improving vision in candidates for intravitreal injection of ocriplasmin. This well-tolerated surgical procedure may be a reliable and predictable alternative for resolving VMT pathology.
dc.description.funderCentro de Retina Medica y Quirurgica, Jalisco, Mexico
dc.fuente.origenWOS
dc.identifier.doi10.1080/02713683.2017.1385086
dc.identifier.eissn1460-2202
dc.identifier.issn0271-3683
dc.identifier.urihttps://doi.org/10.1080/02713683.2017.1385086
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101269
dc.identifier.wosidWOS:000427324400009
dc.issue.numero2
dc.language.isoen
dc.pagina.final212
dc.pagina.inicio208
dc.revistaCurrent eye research
dc.rightsacceso restringido
dc.subjectRetina
dc.subjectvitreomacular traction
dc.subjectocriplasmin
dc.subjectmetamorphopsia
dc.subjectmacular hole
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleSurgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome
dc.typeartículo
dc.volumen43
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas